secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2026-08-14T11:35:47+00:00
Accession:  0001493152-26-037979
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q2 net loss $7.1M; LP-300 PFS benefit deepens; OMAI spin-off
---------------------------------------------------------------------------

- Q2 2026 net loss $7.1M ($0.57/share) vs $4.3M ($0.40) YoY; operating loss down 25% to $3.5M.
- Cash $7.4M at June 30, 2026; raised $4.4M gross from May 14 registered direct offering.
- LP-300 HARMONIC: median PFS 8.9 mo in L858R patients completing 6 cycles (n=9) vs 8.4 mo overall (n=16); HR 0.37; FDA cleared protocol amendments to focus on L858R and extend to 8 cycles.
- EMA cleared LP-184 Phase 1b/2 bladder cancer trial at Rigshospitalet, Denmark; FDA cleared TNBC trial; USPTO Notice of Allowance for three-gene signature.
- Open Medicine AI established as separate company with executed commercial licenses; plans to raise capital at OMAI level.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226037979/0001493152-26-037979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226037979/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer